Refine by
Non Small Cell Lung Cancer Suppliers & Manufacturers
39 companies found
based inHuzhou City, CHINA
Longterm medical is a world-leading custom wound dressings manufacturers that equips healthcare professionals to achieve the best patient, clinical and economic outcomes. We design and supply medical solutions to enhance performance in healthcare – ...
Ultra-thin hydrocolloid dressing, is a 0.6mm wire thickness of flat wound dressing (minimum thickness to 0.3mm), an elastomeric dressing and composed of medical pressure sensitive adhesive, carboxy methyl cellulose (CMC) particles, etc. This ...
based inXiamen, CHINA
Amoy Diagnostics Co., Ltd. (AmoyDx) is an R&D based diagnostic company, focusing on molecular diagnostics for oncology precision medicine. With completely independent intellectual property rights of ADx-ARMS®, Super-ARMS®, ddCapture® and ADx-HANDLE® ...
Neurotrophic tropomyosin-related kinase (NTRK) is a group of high affinity nerve growth factor (NGF) receptors, including tropomyosin receptor kinases (Trk) A, B, and C which are encoded by NTRK1, NTRK2, and NTRK3 genes, respectively. NTRK proteins, ...
based in, MASSACHUSETTS (USA)
MtoZ Biolabs is an integrate contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. The ...
Biosimilars are biological products that are highly similar to an approved original biological drug (reference or brand drug) without any clinically meaningful differences in quality, safety, or efficacy compared to those approved. Biosimilars ...
based inWoodcliff Lake, NEW JERSEY (USA)
Eagle is a specialty pharmaceutical company working to advance safe and efficient injectable treatments for patients across oncology, critical care, and orphan diseases. At Eagle, we are committed to developing innovative drugs that result in ...
Indication: PEMFEXY is indicated in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non-squamous non-small cell ...
based inPalo Alto, CALIFORNIA (USA)
BridgeBio is committed to developing leaders as well as drugs. We are looking for individuals whose passion for creating life-changing medicines will inspire hands-on engagement and the dogged pursuit of novel solutions in the face of adversity. To ...
BridgeBio is developing SHP2 inhibitors as potentially effective additions to the therapeutic arsenal for difficult-to-treat cancers. SHP2, encoded by the PTPN11 gene, links growth factor signaling with the downstream RAS/ERK/MAPK pathway to ...
based inTokyo, JAPAN
Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in 29 countries/regions around the world. With more than 120 years of scientific expertise, our company draws upon a rich ...
ENHERTU (5.4 mg/kg) is approved in more than 50 countries for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received a (or one or more) prior antiHER2-based regimen, either in the metastatic ...
based inVillejuif, FRANCE
Stilla Technologies is the multiplex digital PCR company transforming complex genomic data into actionable insights across a wide range of research and clinical applications including cancer and liquid biopsy studies, cell and gene therapies, ...
based inToronto, ONTARIO (CANADA)
Theralase was one of the first companies in North America to bring CLT to patients and the first company in the world to bring personalized ACT to patients individual tissue characteristics. With our multi-discipline experience in physics, ...
Theralase is laser focused on advancing the cutting-edge Anti-Cancer Therapy (“ACT”) towards commercialization, providing an alternative treatment methodology for Non-Muscle Invasive Bladder Cancer (“NMIBC”) patients ...
based inNantes, FRANCE
OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. Based in Nantes (Head Office) and Paris, OSE Immunotherapeutics ...
Tedopi®, OSE Immunotherapeutics’s most advanced product and therapeutic neo-epitope-based vaccine, is a proprietary combination of nine optimized neo-epitopes, selected and optimized from 5 tumoral antigens to activate specifically T ...
based inMalvern, PENNSYLVANIA (USA)
We are a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. We leverage our expertise in superoxide dismutase ...
Harnessing the Anticancer Power of Hydrogen Peroxide: As cancer cells are more susceptible than normal cells to increased levels of hydrogen peroxide, we believe the conversion of radiation-generated superoxide to hydrogen peroxide by our selective ...
based inBoston, MASSACHUSETTS (USA)
We harness the natural power of the lymph nodes to generate enhanced immune responses against tumors. Our science is defining the future of immunotherapy, with the goal of giving patients who are battling cancer their best possible outcome. We’re ...
Our lymph node-targeted mKRAS cancer vaccine; Our Amphiphile (AMP)-powered lead candidate, ELI-002, generates a robust immune response against mutant Kristen rat sarcoma (mKRAS), with the potential to offer patients a stronger fight against the most ...
based inCopenhagen V, DENMARK
Founded in 1999 in Copenhagen, Denmark, we are a dual-listed, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. We are led by an experienced ...
DuoBody PD-L1x4-1BB (GEN1046) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab’s DuoBody® technology. It is being co-developed by Genmab under an agreement in which the companies share all ...
based inBoston, MASSACHUSETTS (USA)
SOPHiA GENETICS is the creator of a global data-sharing network – we work with customers from over 790 institutions in over 70 countries. Our network advances data-driven medicine to improve health outcomes and economics worldwide. We offer a ...
Unlocking the potential of precision medicine with Artificial Intelligence – enabled data-driven insights. Advance targeted therapy development by harnessing the power of data and multimodal analytics. Advances in molecular and imaging ...
based inSouth San Francisco, CALIFORNIA (USA)
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next-generation cancer therapeutics – antibody drug conjugates, bispecific ...
based inWroclaw, POLAND
Pure Biologics is a biopharmaceutical company focused on the biological drug and non-systemic therapies discovery and development. We operate in the areas of immuno-oncology, autoimmunology, and rare neurological diseases, conducting research based ...
In cancer, a balance between immune system effector and regulatory cells becomes disturbed. Regulatory T cells inhibit the activity of effector cells, including NK cells, a process known as immunosuppression. The PB003 (PureActivator) project ...
based inBeverly, MASSACHUSETTS (USA)
Cellanyx is a growth stage emerging biotech advancing proprietary phenotypic (appearance and dynamics) biomarker tests based on Machine Vision and AI-driven analysis of live single tumor cells to improve risk-stratification and shared clinical ...
Risk stratification of early-stage breast cancer is an active area of research and several commercially available products that are based on genotypic classification. A vexing issue in breast cancer is carcinoma in situ – which has no ...
based inGoettingen, GERMANY
We provide the essential products, technologies and expertise to produce biopharmaceuticals reliably and efficiently. In fact, Sartorius has been pioneering and setting the standards for single-use products that are currently used throughout all ...
Innovation is at the heart of everything we do. Our proprietary drug delivery technology platform, Veltis®, uses engineered recombinant albumin to enhance albumin’s intrinsic characteristics for optimal therapeutic performance of your ...
based inDaejeon, SOUTH KOREA
PANAGENE have been supplying Peptide Nucleic Acid (PNA) worldwide and exclusively since 2006 based on our unique invention of efficient synthesis of PNA with high purity, and nowadays we are possessing the best knowledge on PNA and the largest ...
Lung cancer is a metastatic cancer which the cancer cells are developed in the bronchial tubes or alveoli and grow along the blood vessel or lymphatic vessel. There ...
based inWest Chester, PENNSYLVANIA (USA)
MTTI is a Clinical Stage Company; Transforming the lives of patients burdened with severe and life-threatening diseases. Advancing selective radiotherapeutics, EBTATE targeting neuroendocrine tumors, EBRGD for non-small cell lung cancer and ...
based inGuro-gu, SOUTH KOREA
We provide diagnostic solutions throughout the cancer treatment cycle from early cancer diagnosis to prognostic and companion diagnostics as well as postoperative monitoring. Diagnose cancer as early as possible, when the disease is easiest to ...
Chemotherapy drugs have many side effects such as reduction in white blood cells, hair loss, vomiting because they attack rapidly growing cells without separating cancer cells from normal cells. However targeted therapy drugs have less side effects ...